目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Autotelic Bio Inc
Callitas Therapeutics Inc
Can-Fite BioPharma Ltd
Dare Bioscience Inc
Endoceutics Inc
Freya Pharma Solutions BV
Jupiter Wellness Inc
Kuhnil Pharmaceutical Co Ltd
Lennham Pharmaceuticals Inc
Palatin Technologies Inc
S1 Biopharma Inc
TherapeuticsMD Inc
Thomas Advanced Medical LLC
Viramal Ltd
Female Sexual Dysfunction - Drug Profiles
(buspirone hydrochloride + testosterone) - Drug Profile
Product Description
Mechanism Of Action
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
apomorphine - Drug Profile
Product Description
Mechanism Of Action
bremelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
estradiol - Drug Profile
Product Description
Mechanism Of Action
JW-500 - Drug Profile
Product Description
Mechanism Of Action
KI-1120 - Drug Profile
Product Description
Mechanism Of Action
KI-1128 - Drug Profile
Product Description
Mechanism Of Action
phenylephrine - Drug Profile
Product Description
Mechanism Of Action
prasterone - Drug Profile
Product Description
Mechanism Of Action
Prime Msk Shot - Drug Profile
Product Description
Mechanism Of Action
PrimePro - Drug Profile
Product Description
Mechanism Of Action
S1B-3006 - Drug Profile
Product Description
Mechanism Of Action
S1B-307 - Drug Profile
Product Description
Mechanism Of Action
sildenafil citrate - Drug Profile
Product Description
Mechanism Of Action
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
tadalafil - Drug Profile
Product Description
Mechanism Of Action
testosterone - Drug Profile
Product Description
Mechanism Of Action
testosterone - Drug Profile
Product Description
Mechanism Of Action
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting
Nov 04, 2022: Freya Pharma Solutions: ALETTA pivotal trial well received at ISSM/SMSNA Scientific Meeting
Oct 17, 2022: Palatin announces publication of Vyleesi (bremelanotide) fMRI study in Women with Hypoactive Sexual Desire Disorder (HSDD)
Oct 10, 2022: Female sexual interest drug reaches tipping point with Phase III plans
Sep 28, 2022: Freya Pharma Solutions receives early EMA scientific advice on its upcoming phase 3 clinical trial to confirm efficacy of Lybrido in women suffering from FSIAD
Aug 29, 2022: Dare Bioscience announces interim analysis of phase 2b RESPOND Study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder
Jul 26, 2022: Palatin announces preliminary fourth quarter Vyleesi net product revenue increased 225% over prior quarter
Jun 29, 2022: Freya Pharma solutions announced its application for EMA scientific advice on its phase 3 clinical trial to confirm efficacy of lybrido in women suffering from FSIAD
Apr 12, 2022: Freya Pharma Solutions announces appointment of Dr. Jan van der Mooren as chief medical officer, to guide its pivotal phase 3 clinical trial with Lybrido against FSIAD
May 04, 2021: Palatin announces U.S. patent term extension for Vyleesi (bremelanotide injection)
Mar 24, 2021: Dare Bioscience announces initiation of phase 2b RESPOND study of sildenafil cream, 3.6% in women with female sexual arousal disorder
Aug 25, 2020: Knight and TherapeuticsMD announce Health Canada approval of IMVEXXY
Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder
Dec 11, 2019: Dare Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder
Oct 30, 2019: Knight and TherapeuticsMD announce filing of new drug submission for Joyesta in Canada
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Female Sexual Dysfunction, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Female Sexual Dysfunction - Pipeline by Autotelic Bio Inc, 2022
Female Sexual Dysfunction - Pipeline by Callitas Therapeutics Inc, 2022
Female Sexual Dysfunction - Pipeline by Can-Fite BioPharma Ltd, 2022
Female Sexual Dysfunction - Pipeline by Dare Bioscience Inc, 2022
Female Sexual Dysfunction - Pipeline by Endoceutics Inc, 2022
Female Sexual Dysfunction - Pipeline by Freya Pharma Solutions BV, 2022
Female Sexual Dysfunction - Pipeline by Jupiter Wellness Inc, 2022
Female Sexual Dysfunction - Pipeline by Kuhnil Pharmaceutical Co Ltd, 2022
Female Sexual Dysfunction - Pipeline by Lennham Pharmaceuticals Inc, 2022
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, 2022
Female Sexual Dysfunction - Pipeline by S1 Biopharma Inc, 2022
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, 2022
Female Sexual Dysfunction - Pipeline by Thomas Advanced Medical LLC, 2022
Female Sexual Dysfunction - Pipeline by Viramal Ltd, 2022
Female Sexual Dysfunction - Dormant Projects, 2022
Female Sexual Dysfunction - Dormant Projects, 2022 (Contd..1)
Female Sexual Dysfunction - Dormant Projects, 2022 (Contd..2)
Female Sexual Dysfunction - Discontinued Products, 2022

List of Figures
Number of Products under Development for Female Sexual Dysfunction, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022